Dosage Adjustment for Patients with Impaired Renal Function WELLBUTRIN SR should be used with caution in patients with renal impairment and a reduced frequency and/ or dose should be considered (see CLINICAL PHARMACOLOGY and PRECAUTIONS). HOW SUPPLIED WELLBUTRIN SR Sustained-Release Tablets, 100 mg of bupropion hydrochloride, are blue, round, biconvex, film-coated tablets printed with "WELLBUTRIN SR 100" in bottles of 60 (NDC 0173-0947-55) tablets. WELLBUTRIN SR Sustained-Release Tablets, 150 mg of bupropion hydrochloride, are purple, round, biconvex, film-coated tablets printed with "WELLBUTRIN SR 150" in bottles of 60 (NDC 0173-0135-55) tablets. WELLBUTRIN SR Sustained-Release Tablets, 200 mg of bupropion hydrochloride, are light pink, round, biconvex, film-coated tablets printed with "WELLBUTRIN SR 200" in bottles of 60 (NDC 0173-0722-00) tablets. Store at controlled room temperature, 20° to 25° C (68° to 77° F) [see USP]. Dispense in a tight, light-resistant container as defined in the USP. Distributed by: GlaxoSmithKline, Research Triangle Park, NC 27709 Manufactured by: GlaxoSmithKline Research Triangle Park, NC 27709 or DSM Pharmaceuticals, Inc. Greenville, NC 27834 ©2002, GlaxoSmithKline. All rights reserved. October 2002 RL-1151 | ||||
Email this article
Printer friendly
Bookmark this pageadvertisement
